文献速递免疫规划传染病防控与疫情报告

重组保护性抗原炭疽疫苗(GC1109)的免疫原性与安全性评价:一项Ⅱ期、剂量确证、随机、双盲、安慰剂对照研究

Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study.
PubMed 文献 · Vaccine · 2025-10-08

该Ⅱ期随机双盲安慰剂对照试验在19至65岁健康成人中评估四剂肌肉注射GC1109(1.0 mL,第0、4、8、32周)的免疫原性与安全性。GC1109组全部受试者第36周TNA NF50≥0.56(100%,95%CI 97.6-100.0),达到主要终点预设标准;瘙痒是唯一显著更频的征集性不良事件,严重不良事件罕见且与接种无关。

要点

  • GC1109组第36周TNA NF50≥0.56的比例为100%(95%CI 97.6-100.0)。
  • TNA与抗PA IgG水平在第36周达峰,之后下降。
  • 瘙痒是唯一显著更频的征集性不良事件;严重不良事件罕见且与接种无关。

核心结论

  • 四剂GC1109具有免疫原性且总体耐受性良好。
  • 需进一步研究探索合适的加强策略并在更大人群中评估安全性。

研究设计与样本

  • 随机、双盲、安慰剂对照Ⅱ期试验,纳入19至65岁健康志愿者。
  • 受试者按3:1比例分配至GC1109(1.0 mL)组或安慰剂组,于第0、4、8、32周肌肉注射。
  • 免疫原性采用毒素中和抗体(TNA)滴度与抗PA IgG水平评估,主要终点为第36周TNA 50%中和因子(NF50)≥0.56的受试者比例。
  • 安全性通过征集性和非征集性不良事件(AE)评估。

主要发现

  • GC1109组全部受试者第36周达到TNA NF50≥0.56(100%,95%CI 97.6-100.0),达到主要终点预设标准。
  • TNA与抗PA IgG水平在第36周达峰,之后下降。
  • 瘙痒是唯一在GC1109组显著更频的征集性不良事件。
  • 严重不良事件罕见且与接种无关。

关键数值与推荐

  • 主要终点预设标准为第36周TNA NF50≥0.56的受试者比例。
  • GC1109组第36周TNA NF50≥0.56比例为100%(95%CI 97.6-100.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需进一步研究探索合适的加强策略并在更大人群中评估安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: GC1109, a novel recombinant protective antigen (PA) anthrax vaccine, has demonstrated promising immunogenicity in previous dose-finding trials. This study evaluated the immunogenicity and safety of four intramuscular doses of GC1109 in healthy adults. METHODS: This randomized, double-blind, placebo-controlled phase 2 trial enrolled healthy volunteers aged 19 to 65 years. Participants were assigned in a 3: 1 ratio to receive either GC1109 (1.0 mL) or placebo at weeks 0, 4, 8, and 32. Immunogenicity was assessed using toxin neutralization antibody (TNA) titers and anti-PA IgG levels. The primary endpoint was the proportion of vaccine recipients achieving a TNA 50 % neutralization factor (NF50) ≥ 0.56 at week 36. Safety was evaluated through solicited and unsolicited adverse events (AEs). RESULTS: All participants in the GC1109 group achieved TNA NF50 ≥ 0.56 at week 36 (100 %, 95 % confidence interval: 97.6-100.0) and the predefined criterion for the primary endpoint was met. TNA and anti-PA IgG levels peaked at week 36 but declined thereafter. Pruritus was the only solicited AE significantly more frequent in the GC1109 group; serious AEs were rare and unrelated to vaccination. CONCLUSIONS: Four doses of GC1109 were immunogenic and generally well-tolerated. Further studies are needed to explore appropriate boosting strategies and evaluate safety in larger populations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kang CK, Im YJ, Kim DY, et al. Immunogenicity and safety evaluation of a recombinant protective antigen anthrax vaccine (GC1109): A phase II, dose-confirmed, randomized, double-blind, placebo-controlled study. Vaccine. 2025. PMID: 41067086. doi:10.1016/j.vaccine.2025.127819

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。